文献速递眼底病与葡萄膜炎

无脉络膜症基因治疗后视网膜敏感性变化

CHANGES IN RETINAL SENSITIVITY AFTER GENE THERAPY IN CHOROIDEREMIA.
PubMed 文献 · Retina · 2020-01-01

PURPOSE: Choroideremia (CHM) is a rare inherited retinal degeneration resulting from mutation of the CHM gene, which results in absence of functional Rab escort protein 1 (REP1).…

要点

  • AAV2-REP1基因治疗在部分无脉络膜症患者中可维持或改善视力
  • 5/6患者视网膜平均敏感度、峰值敏感度和注视固定面积改善
  • 不良事件与玻璃体切割联合视网膜下注射手术操作一致

核心结论

  • AAV2-REP1基因治疗可维持、部分病例改善无脉络膜症患者视力,但需更长期随访确认获益是否持续。

研究设计与样本

  • THOR研究(NCT02671539)为2期、开放标签、单中心、随机研究,纳入6例51-60岁男性无脉络膜症患者。

主要发现

  • 研究眼最佳矫正视力变化为-4至+1 ETDRS字母(4例轻微变化),1例增加17字母,另1例丧失14字母;对照眼变化为-2至+4字母。
  • 5/6患者记录到平均视网膜敏感度改善2.3(95%CI 4.0)dB、峰值视网膜敏感度改善2.8(95%CI 3.5)dB、注视固定面积变化-36.1(95%CI 66.9)度。
  • 研究眼与对照眼在解剖学终点变化上相似。
  • 不良事件与手术操作一致。

临床怎么用

  • 对于无脉络膜症患者,AAV2-REP1基因治疗可能作为维持或改善视功能的干预选项,但需在专业中心由经验丰富的术者实施。
  • 治疗后应密切监测视力、视网膜敏感度和注视固定面积变化,并长期随访评估获益持续性。

局限性

  • 开放标签设计可能引入偏倚;对照眼变化和解剖学终点相似提示需谨慎解读功能改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Choroideremia (CHM) is a rare inherited retinal degeneration resulting from mutation of the CHM gene, which results in absence of functional Rab escort protein 1 (REP1). We evaluated retinal gene therapy with an adeno-associated virus vector that used to deliver a functional version of the CHM gene (AAV2-REP1). METHODS: THOR (NCT02671539) is a Phase 2, open-label, single-center, randomized study. Six male patients (51-60 years) with CHM received AAV2-REP1, by a single 0.1-mL subretinal injection of 10 genome particles during vitrectomy. Twelve-month data are reported. RESULTS: In study eyes, 4 patients experienced minor changes in best-corrected visual acuity (-4 to +1 Early Treatment Diabetic Retinopathy Study [ETDRS] letters); one gained 17 letters and another lost 14 letters. Control eyes had changes of -2 to +4 letters. In 5/6 patients, improvements in mean (95% confidence intervals) retinal sensitivity (2.3 [4.0] dB), peak retinal sensitivity (2.8 [3.5] dB), and gaze fixation area (-36.1 [66.9] deg) were recorded. Changes in anatomical endpoints were similar between study and control eyes. Adverse events were consistent with the surgical procedure. CONCLUSION: Gene therapy with AAV2-REP1 can maintain, and in some cases, improve, visual acuity in CHM. Longer term follow-up is required to establish whether these benefits are maintained.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Fischer MD, Ochakovski GA, Beier B, et al. CHANGES IN RETINAL SENSITIVITY AFTER GENE THERAPY IN CHOROIDEREMIA. Retina. 2020. PMID: 30308560. doi:10.1097/IAE.0000000000002360

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。